Cebiotex Seeks a New Investor for Its Oncology Patent and Targets the US and China

Cebiotex, the  Catalan start-up specializing in the development of cancer drugs is looking for a buyer for its multi-application cancer patent, explains Joan Bertrán, CEO and Chairman of the Board of Directors of Cebiotex, to PlantaDoce. In parallel, in the last quarter of the year, the company will open a new round of financing with which it hopes to make the leap to the United States and China.

Cebiotex is in phase I of development of its new oncological drug against pancreatic, ovarian, and breast cancer and indications that require surgery. “We anticipate that this drug will be launched on the market in 2027 and in less than a year a company will buy the patent,” said Bertrán.

The CEO of Cebiotex praises the progress of the phase I tests and points out that the new round of financing will be much larger than those previously carried out. Since 2015, Cebiotex has carried out four rounds and has raised more than seven million euros. “The amount is not clear to me, but I am sure that it will be greater than the previous ones,” explained Bertrán.

Read more about Cebiotex and find other interesting financial news with the Born2Invest mobile app.

Cebiotex has carried out four rounds of financing since it was established in 2012, raising more than seven million euros

In addition,  the Catalan company intends to expand internationally and enter the US and Chinese markets. With this growth abroad, it also intends to increase the company’s staff in all its areas.

The technology that Cebiotex implements is its own for the development of its drugs. So far it has three stem cell reproduction machines, called  Black Box. “I would like to highlight that our company is autonomous in the creation of our medicines, meaning that we can sell the licenses or patents to the investor that suits us best,” says Bertrán.

Currently, Cebiotex maintains a strategic alliance with the Catalan pharmaceutical company Prasfarma, a supplier of cell membranes. The biotechnology company uses the facilities of the pharmaceutical company located in Manlleu (Barcelona) to be able to work with high-powered molecules. From this factory, the membranes are exported to hospitals.

Cebiotex maintains a strategic alliance with the Catalan pharmaceutical Prasfarma

Cebiotex’s objective in the near future is to sign an agreement with an international pharmaceutical company so that they buy the patents for its products, but it places the condition on companies that wish to acquire their licenses “that they do not obviate the pediatric option of their drugs.”

Joan Bertrán has a degree in Textile Engineering. Bertrán has been part of the board of directors of companies such as Courtels International Fabrics (United Kingdom), Penn Elastic (Germany), Punto Blanco, Relats and Indesmalla (Spain).

The manager is the largest shareholder of Cebiotex, as well as CEO. Cebiotex is also made up of Lucas Krauel, co-founder and surgical director, and José Antonio Tornero, co-founder and technology manager.

__

(Featured image by stevepb via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.